These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 1432609)

  • 1. In vitro and in vivo anticalcification effects of novel bishydroxyiminophosphonates.
    Golomb G; Schlossman A; Eitan Y; Saadeh H; Van Gelder JM; Breuer E
    J Pharm Sci; 1992 Oct; 81(10):1004-7. PubMed ID: 1432609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo.
    Golomb G; Schlossman A; Saadeh H; Levi M; Van Gelder JM; Breuer E
    Pharm Res; 1992 Jan; 9(1):143-8. PubMed ID: 1589400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anticalcification and antiresorption effects of bisacylphosphonates.
    Van Gelder JM; Breuer E; Ornoy A; Schlossman A; Patlas N; Golomb G
    Bone; 1995 May; 16(5):511-20. PubMed ID: 7654466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo effects of tetrakisphosphonates on bone resorption, tumor osteolysis, ectopic calcification, and macrophages.
    Van Gelder JM; Breuer E; Schlossman A; Ornoy A; Mönkkönen J; Similä J; Klenner T; Stadler H; Krempien B; Patlas N; Golomb G
    J Pharm Sci; 1997 Mar; 86(3):283-9. PubMed ID: 9050794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders.
    Cohen H; Solomon V; Alferiev IS; Breuer E; Ornoy A; Patlas N; Eidelman N; Hägele G; Golomb G
    Pharm Res; 1998 Apr; 15(4):606-13. PubMed ID: 9587958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating.
    Golomb G; Dixon M; Smith MS; Schoen FJ; Levy RJ
    J Pharm Sci; 1987 Apr; 76(4):271-6. PubMed ID: 3110404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro effects of anticalcification treatment on the calcium uptake of bioprosthetic materials.
    Dahm M; Prüfer D; Krummenauer F; Mayer E; Hafner G; Groh E; Oelert H
    J Heart Valve Dis; 1998 May; 7(3):336-9. PubMed ID: 9651849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation and evaluation of chitosan microspheres containing bisphosphonates.
    Patashnik S; Rabinovich L; Golomb G
    J Drug Target; 1997; 4(6):371-80. PubMed ID: 9239577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AL preincubation inhibits calcification of bioprosthetic heart valve tissue in the rat subdermal model.
    Webb CL; Schoen FJ; Levy RJ
    ASAIO Trans; 1988; 34(3):855-9. PubMed ID: 3143392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of leaflet calcification of bioprosthetic heart valves with diphosphonate injection therapy. Experimental studies of optimal dosages and therapeutic durations.
    Levy RJ; Schoen FJ; Lund SA; Smith MS
    J Thorac Cardiovasc Surg; 1987 Oct; 94(4):551-7. PubMed ID: 3116348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism.
    Fleisch H
    Recent Results Cancer Res; 1989; 116():1-28. PubMed ID: 2669065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of different anticalcification treatments for stentless aortic bioprostheses.
    Walther T; Falk V; Diegeler A; Rauch T; Weigl C; Gummert J; Autschbach R; Mohr FW
    Thorac Cardiovasc Surg; 1999 Feb; 47(1):23-5. PubMed ID: 10218616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate.
    Levy RJ; Wolfrum J; Schoen FJ; Hawley MA; Lund SA; Langer R
    Science; 1985 Apr; 228(4696):190-2. PubMed ID: 3919445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental basis for the use of bisphosphonates in Paget's disease of bone.
    Fleisch H
    Clin Orthop Relat Res; 1987 Apr; (217):72-8. PubMed ID: 3549097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of bioprosthetic heart valve calcification with aminodiphosphonate covalently bound to residual aldehyde groups.
    Webb CL; Benedict JJ; Schoen FJ; Linden JA; Levy RJ
    Ann Thorac Surg; 1988 Sep; 46(3):309-16. PubMed ID: 3137904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition by diphosphonate compounds of calcification of porcine bioprosthetic heart valve cusps implanted subcutaneously in rats.
    Levy RJ; Hawley MA; Schoen FJ; Lund SA; Liu PY
    Circulation; 1985 Feb; 71(2):349-56. PubMed ID: 3917378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo and in vitro models of calcification in porcine aortic valve cusps.
    Mako WJ; Vesely I
    J Heart Valve Dis; 1997 May; 6(3):316-23. PubMed ID: 9183732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In search of the best xenogeneic material for a paediatric conduit: an experimental study.
    Zhuravleva IY; Nichay NR; Kulyabin YY; Timchenko TP; Korobeinikov AA; Polienko YF; Shatskaya SS; Kuznetsova EV; Voitov AV; Bogachev-Prokophiev AV; Karaskov AM
    Interact Cardiovasc Thorac Surg; 2018 May; 26(5):738-744. PubMed ID: 29346675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled release of diphosphonates from synthetic polymers to inhibit calcification.
    Golomb G
    J Biomater Appl; 1987 Oct; 2(2):266-89. PubMed ID: 3144594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The angiotensin II type 1 receptor blocker losartan attenuates bioprosthetic valve leaflet calcification in a rabbit intravascular implant model.
    Shin HJ; Kim DH; Park HK; Park YH
    Eur J Cardiothorac Surg; 2016 Dec; 50(6):1045-1052. PubMed ID: 27261074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.